ARS Pharma wins EU approval of epinephrine nasal spray

ozgurcankaya/E+ via Getty Images The European Commission has granted approval to ARS Pharmaceuticals' ( NASDAQ: SPRY ) EUR neffy , an epinephrine nasal spray for the emergency treatment of allergic reactions. The approval was supported by trial data from more than 700 patients as well as scientific literature. The U.

S. FDA approved the drug, under the name neffy , earlier in August . More on ARS Pharmaceuticals ARS stock jumps 13% on FDA approval of epinephrine nasal spray (update) ARS Pharmaceuticals, Inc.

(SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call Transcript ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles Raymond James ups ARS to strong buy, cites FDA neffy approval.